analysis

Twitter: expediting critical research analysis

Midostaurin: the first drug to receive approval for AML since 2000

Current understandings of ALL approaches

Challenges with the identification of ALL subtypes

Myeloma XI trial: impact of MRD on treatment response in MM

Multiple myeloma highlights at ASH 2017

Results of the MURANO study for CLL

ASH 2017: CLL combination therapy highlights

“Sequential triple-T” therapy for CLL

Impacts of the MURANO study for future CLL treatment

ASH 2017: combination therapy for CLL highlights

Bendamustine plus rituximab vs. standard therapy for advanced CLL

Front-line use of ibrutinib for CLL in a real-world setting

Retrospective multicenter analysis of venetoclax-treated CLL patients

Triple therapy for CLL: pembrolizumab, ublituximab and umbralisib

Checkpoint inhibitor/bispecific antibody combo: REGN2810 and REGN1979 in B-lymphoid malignancies